Rifampicin inhibits the retinal neovascularization in vitro and in vivo

Experimental Eye Research

Volumn 86, Issue 1, 2008, Pages 131-137

  Chikaraishi, Yuichi ^a   Matsunaga, Nozomu ^a   Shimazawa, Masamitsu ^a   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

angiogenesis; neovascularization; oxygen induced retinopathy; rifampicin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RIFAMPICIN;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY;

ANGIOGENESIS INHIBITORS; ANIMALS; BODY WEIGHT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXYGEN; PHOSPHORYLATION; RETINAL NEOVASCULARIZATION; RIFAMPIN;

EID: 36749061332     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2007.10.003     Document Type: Article

References (29)

1. Acocella G., Buniva G., Flauto V., and Nicolis F.B. Absorption and elimination of the antibiotic rifampicin in newborns and children. Proceedings of the 6th International Congress of Chemotherapy (1969), University of Tokyo Press, Tokyo 755-760
2. Adhvaryu S.G., and Shah V.C. Cell proliferation and nucleic acid synthesis in cells treated with rifampin. Indian J. Exp. Biol. 22 (1984) 350-352
3. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., and Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1432-1444
4. Chikaraishi Y., Shimazawa M., and Hara H. New quantitative analysis, using high-resolution images, of oxygen-induced retinal neovascularization in mice. Exp. Eye. Res. 84 (2007) 529-536
5. Chua C.C., Hamdy R.C., and Chua B.H. Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free. Radic. Biol. Med. 25 (1998) 891-897
6. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (2004) 2805-2816
7. Hooper C.Y., and Guymer R.H. New treatments in age-related macular degeneration. Clin. Experiment. Ophthalmol. 31 (2003) 376-391
8. Isefuku S., Joyner C.J., and Simpson A.H. Toxic effect of rifampicin on human osteoblast-like cells. J. Orthop. Res. 19 (2001) 950-954
9. Kilic U., Kilic E., Lingor P., Yulug B., and Bahr M. Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. Acta Neuropathol. (Berl.) 108 (2004) 65-68
10. Lu M., Kuroki M., Amano S., Tolentino M., Keough K., Kim I., Bucala R., and Adamis A.P. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. 101 (1998) 1219-1224
11. Lyle W.M., Cullen A.P., and Charman W.N. Role of lasers in eye care. Optom. Vis. Sci. 70 (1993) 136-151
12. Mainster M.A. Decreasing retinal photocoagulation damage: principles and techniques. Semin. Ophthalmol. 14 (1999) 200-209
13. Mindermann T., Landolt H., Zimmerli W., Rajacic Z., and Gratzl O. Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J. Antimicrob. Chemother. 31 (1993) 731-737
14. Mindermann T., Zimmerli W., and Gratzl O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob. Agents Chemother. 42 (1998) 2626-2629
15. Oida Y., Kitaichi K., Nakayama H., Ito Y., Fujimoto Y., Shimazawa M., Nagai H., and Hara H. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. Brain. Res. 1082 (2006) 196-204
16. Penn J.S., Tolman B.L., and Bullard L.E. Effect of a water-soluble vitamin E analog, trolox C, on retinal vascular development in an animal model of retinopathy of prematurity. Free. Radic. Biol. Med. 22 (1997) 977-984
17. Redondo P., Bandres E., Solano T., Okroujnov I., and Garcia-Foncillas J. Vascular endothelial growth factor (VEGF) and melanoma. N-acetylcysteine downregulates VEGF production in vitro. Cytokine 12 (2000) 374-378
18. Reynolds J.F., and Martindale W. The Extra Pharmacopoeia. 30th ed. (1993), The Pharmaceutical Press, London
19. Reynolds J.D. The management of retinopathy of prematurity. Paediatr. Drugs 3 (2001) 263-272
20. Rodriguez J.A., Nespereira B., Perez-Ilzarbe M., Eguinoa E., and Paramo J.A. Vitamins C and E prevent endothelial VEGF and VEGFR-2 overexpression induced by porcine hypercholesterolemic LDL. Cardiovasc. Res. 65 (2005) 665-673
21. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., and Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1419-1431
22. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., and D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35 (1994) 101-111
23. Subak-Sharpe J.H., Pennington T.H., Szilagyi J.F., Timbury M.C., and Williams J.F. The effect of rifampicin on mammalian viruses and cells. In: Silvestri L. (Ed). RNA Polymerase and Transcription. Proceedings of the Lepetit Colloquium (1970), North Holland Publishing Co., Amsterdam 260-286
24. Thornsberry C., Hill B.C., Swenson J.M., and McDougal L.K. Rifampin: spectrum of antibacterial activity. Rev. Infect. Dis. 5 Suppl. 3 (1983) S412-S417
25. Tomiyama T., Shoji A., Kataoka K., Suwa Y., Asano S., Kaneko H., and Endo N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem. 271 (1996) 6839-6844
26. Whiteman M., and Halliwell B. Prevention of peroxynitrite-dependent tyrosine nitration and inactivation of alpha1-antiproteinase by antibiotics. Free Radic. Res. 26 (1997) 49-56
27. Wu L.W., Mayo L.D., Dunbar J.D., Kessler K.M., Baerwald M.R., Jaffe E.A., Wang D., Warren R.S., and Donner D.B. Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J. Biol. Chem. 275 (2000) 5096-5103
28. Yulug B., Kilic U., Kilic E., and Bahr M. Rifampicin attenuates brain damage in focal ischemia. Brain. Res. 996 (2004) 76-80
29. Ziglam H.M., Daniels I., and Finch R.G. Immunomodulating activity of rifampicin. J. Chemother. 16 (2004) 357-361